Comparative Pharmacology
Head-to-head clinical analysis: DELFLEX LM W DEXTROSE 3 5 IN PLASTIC CONTAINER versus DIANEAL LOW CALCIUM W DEXTROSE 2 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DELFLEX LM W DEXTROSE 3 5 IN PLASTIC CONTAINER versus DIANEAL LOW CALCIUM W DEXTROSE 2 5 IN PLASTIC CONTAINER.
DELFLEX-LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER vs DIANEAL LOW CALCIUM W/DEXTROSE 2.5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DELFLEX-LM W/ DEXTROSE 3.5% is a peritoneal dialysis solution. Its mechanism of action involves osmotic ultrafiltration across the peritoneal membrane, facilitated by high dextrose concentration, to remove excess fluid and waste products (e.g., urea, creatinine) from the blood in patients with end-stage renal disease.
The dextrose component provides osmotic pressure for peritoneal dialysis, promoting ultrafiltration of fluid and removal of solutes. Calcium and other electrolytes maintain physiologic balance.
Intraperitoneal: 1.5% to 4.25% dextrose solution; 2 to 2.5 L per exchange, typically 4 exchanges per 24 hours; dwell time 4 to 6 hours.
Intraperitoneal: Continuous ambulatory peritoneal dialysis (CAPD): 2-2.5 L per exchange, 4-5 exchanges per day; Continuous cyclic peritoneal dialysis (CCPD): 2-2.5 L per exchange, 3-5 nocturnal exchanges plus one daytime dwell.
None Documented
None Documented
Not applicable for dextrose; for lactate/bicarbonate buffer components, half-life is approximately 2-4 hours in peritoneal cavity with systemic absorption minimal. Clinical context: continuous dialysis maintains steady-state.
Not applicable as a solution; glucose half-life ~20-30 min in circulation; clinical effect duration corresponds to dwell time (4-6 hours for standard exchange)
Peritoneal dialysis: Removal of waste products (urea, creatinine) via peritoneal membrane; approximately 60-80% of urea is removed during a 4-6 hour dwell. Biliary/fecal: minimal (<5%). Renal: negligible as drug is primarily used in renal failure.
Primarily eliminated via peritoneal dialysis; glucose is metabolized systemically and excreted as CO2 and water; <5% renal excretion of metabolites
Category C
Category C
Peritoneal Dialysis Solution
Peritoneal Dialysis Solution